Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2023 | Buy | Sidoti | |
| 7/7/2022 | $78.00 → $53.00 | Hold → Underperform | Jefferies |
| 4/14/2022 | $86.00 | Neutral | DA Davidson |
Sidoti initiated coverage of USANA with a rating of Buy
Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously
DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)
8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)
8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)
SALT LAKE CITY, Nov. 11, 2025 /PRNewswire/ -- USANA (NYSE:USNA), the global leader in cellular nutrition, is thrilled to announce that its fan-favorite MagneCal D supplement has officially earned the coveted ConsumerLab.com Seal of Approval—a gold-standard recognition for purity, potency, and scientific excellence.* With millions of Americans looking for ways to maintain their bone density, getting enough calcium, magnesium, and vitamin D isn't just a good idea—it's essential. That's where MagneCal D comes in, combining powerful nutrients to help maintain strong bones, keep yo
Community-wide effort addresses growing food insecurity among Utah children and families SALT LAKE CITY, Nov. 6, 2025 /PRNewswire/ -- In a powerful response to growing food insecurity affecting Utah families and the recent federal SNAP cutbacks, the USANA Foundation joined forces with community partners and volunteers on Wednesday, November 5, to assemble 3,000 bags of food for children and families facing food insecurity. The large-scale event, held at the USANA Foundation Headquarters in West Valley City, brought together hundreds of volunteers from organizations including t
SALT LAKE CITY, Nov. 3, 2025 /PRNewswire/ -- As business leaders worldwide focus on re-energizing workforces after years of upheaval, Kevin Guest, Executive Chairman of USANA Health Sciences (NYSE:USNA), is urging CEOs to lead with renewed authenticity, empathy, and moral clarity—principles he calls "the real foundation of sustainable success." "No doubt, technology and strategy will always matter," Guest said. "But what truly binds a company together is trust. When people feel seen, valued, and inspired, they do their best work, and that's how you create a culture that thrive
USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 27, 2025. Key Financial Results Third Quarter 2025 vs. Third Quarter 2024 Net sales of $214 million versus $200 million, representing 7% year-over-year growth. Net loss of -$6.5 million versus net earnings of $10.6 million. Diluted EPS of -$0.36 as compared with $0.56. Adjusted diluted EPS(1) of -$0.15 as compared with $0.56. Adjusted EBITDA(2) of $13.8 million versus $24.6 million. Direct selling Active Customers of 388,000 versus 452,000. Hiya Active Monthly Subscribers of 193,400. Q3 2025 Financial Performance Consolidated Results
USANA Health Sciences, Inc. (NYSE:USNA) ("the Company," "USANA") today announced that it has updated the timing of the release of its third quarter 2025 financial results, which had previously been scheduled for Tuesday, October 21, 2025. The Company will now report third quarter 2025 financial results after the close of market on Wednesday, October 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the follow
USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary results for the third quarter ended September 27, 2025. The Company anticipates third quarter 2025 net sales will be approximately $214 million, which compares with $200 million in the prior-year period. Earnings from operations are expected to be $1.2 million for the current-year quarter, or 0.6% of net sales, as compared to $15.6 million in the third quarter of 2024. "Third quarter operating results came in below expectations, primarily due to softer-than-expected sales and Brand Partner productivity during the rollout of our enhanced Brand Partner compensation plan," said Jim Brown, President and Chief Executive Office
NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c
SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has
Dr. Kathryn Armstrong brings 17 years of scientific expertise to the company SALT LAKE CITY, Jan. 22, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, is proud to announce that Dr. Kathryn Armstrong, Ph.D., will be assuming the role of chief scientific officer at the company. Kathryn has served as USANA's executive vice president of research and development since July of 2024. Kathryn's predecessor, Dr. Rob Sinnott, announced his retirement at the end of 2024, but will continue to assist in the company's pursuit for scientific excellence as its senior scientific fellow.
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)